Olanzapine is indicated for the following conditions-

• schizophrenia
• bipolar I disorder

Schizophrenia

Bipolar Disorder

• Schizophrenia in adults
• • Oral: Start at 5-10 mg once daily
  • Target: 10 mg/day within several days 
• Schizophrenia in adolescents
• • Oral: Start at 2.5-5 mg once daily
  • Target: 10 mg/day 
• Bipolar I Disorder (manic or mixed episodes) in adults 
• • Oral: Start at 10 or 15 mg once daily 
• Bipolar I Disorder (manic or mixed episodes) in adolescents
• • Oral: Start at 2.5-5 mg once daily;
  • Target: 10 mg/day 
• Bipolar I Disorder (manic or mixed episodes) with lithium or valproate in adults
• • Oral: Start at 10 mg once daily 
• Agitation associated with Schizophrenia and Bipolar I Mania in adults
• • IM: 10 mg (5 mg or 7.5 mg when clinically warranted) Assess for orthostatic hypotension prior to subsequent dosing (max. 3 doses 2-4 hrs apart) 
• Depressive Episodes associated with Bipolar I Disorder in adults
• • Oral in combination with fluoxetine: Start at 5 mg of oral olanzapine and 20 mg of fluoxetine once daily
• Depressive Episodes associated with Bipolar I Disorder in children and adolescents 
• • Oral in combination with fluoxetine: Start at 2.5 mg of oral olanzapine and 20 mg of fluoxetine once daily
• Treatment Resistant Depression in adults
• • Oral in combination with fluoxetine: Start at 5 mg of oral olanzapine and 20 mg of fluoxetine once daily 

• Schizophrenia (Adults) – postural hypotension, constipation, weight gain, dizziness, personality disorder, akathisia
• Schizophrenia (Adolescents) – sedation, weight increased, headache, increased appetite, dizziness, abdominal pain, pain in extremity, fatigue, dry mouth
• Manic or Mixed Episodes, Bipolar I Disorder (Adults) – asthenia, dry mouth, constipation, increased appetite, somnolence, dizziness, tremor 
• Manic or Mixed Episodes, Bipolar I Disorder (Adolescents) – sedation, weight increased, increased appetite, headache, fatigue, dizziness, dry mouth, abdominal pain, pain in extremity 

Hypotension

Constipation

Headache

Asthenia

• Elderly Patients with Dementia-Related Psychosis: Increased risk of death and increased incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack).
• Suicide: The possibility of a suicide attempt is inherent in schizophrenia and in bipolar I disorder, and close supervision of high-risk patients should accompany drug therapy.
• Neuroleptic Malignant Syndrome: Manage with immediate discontinuation and close monitoring.
• Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes including hyperglycemia, dyslipidemia, and weight gain.
• Orthostatic Hypotension: Orthostatic hypotension associated with dizziness, tachycardia, bradycardia and, in some patients, syncope, may occur especially during initial dose titration. Use caution in patients with cardiovascular disease, cerebrovascular disease, and those conditions that could affect hemodynamic responses.
• Seizures: Use cautiously in patients with a history of seizures or with conditions that potentially lower the seizure threshold.